Profil bibliographique

Michael R. Hayden

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

1138Publications signalées

87123Citations signalées

3Affiliations récentes

Institutions déclarées

University of British Columbia iCo Therapeutics (Canada)BC Children's Hospital

Domaines associés

Genetic Neurodegenerative DiseasesMitochondrial Function and PathologyNeurological disorders and treatmentsLipid metabolism and disordersCholesterol and Lipid Metabolism

Publications récentes

Accès ouvert 2026 preprintOpenAlex

Synonymous HTT CAA/CCA-loss variants associated with early Huntington disease onset enhance toxicity beyond somatic instability

Glen Lester Sequiera, Sophia C. Gjervan, Ryan T. McCallum, Jia Feng et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 preprintOpenAlex

Proteomic profiling of baseline CSF and serum from HDClarity identifies signatures for Huntington disease staging and stratification

Nicholas S. Caron, Inês Caldeira Brás, Jessica C. Barron, Emily M. Harvey et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 preprintOpenAlex

Loss of interruption in the HTT CAG repeat is associated with increased somatic expansion and loss of medium spiny neurons in HD

Chris Kay, Jessica Q. Dawson, Kert Mätlik, Hailey Findlay Black et autres

1 citationbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 preprintOpenAlex

Long-Term Slowing of Progression in Huntington’s Disease with Pridopidine Treatment

Ralf Reilmann, Andrew M. Tan, Anne E Rosser, Kelly Chen et autres

0 citationsmedRxiv

Accès ouvert 2025 articleOpenAlex

Sequence Variants in Small CAG Repeat Expansions of the HTT Gene and Disease Onset and Progression in Huntington Disease

Anna Heinzmann, Emilien Petit, Jessica Dawson, Chris Kay et autres

4 citationsNeurology

Accès ouvert 2025 articleOpenAlex

Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases

Noga Gershoni Emek, Andrew M. Tan, Michal Geva, Andrea Fekete et autres

8 citationsPharmaceuticals

Accès ouvert 2025 articleOpenAlex

Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial

Michal Geva, Y. Paul Goldberg, Melanie Leitner, Andrés Cruz-Herranz et autres

2 citationsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Accès ouvert 2025 articleOpenAlex

Blood RNA biomarkers and a point-of-care elastase assay for detecting host immune activation in suspected sepsis: Trajectory matters

John Lafleur, Eduard Shaykhinurov, J. F. Perkins, Richard Wargowsky et autres

0 citationsPLoS ONE

Accès ouvert 2025 preprintOpenAlex

Age, Chemistry, and Kinematics of the Inner Galaxy Revealed by MUSE

Z. Wang, Michael R. Hayden, Joss Bland‐Hawthorn, Anil C. Seth et autres

0 citationsarXiv (Cornell University)

2025 articleOpenAlex

Sigma-2 Receptor Antagonism Enhances the Neuroprotective Effects of Pridopidine, a Sigma-1 Receptor Agonist, in Huntington’s Disease

Jing Jin, Randal Hand, May Meltzer, Carmen Abate et autres

0 citationsMolecular Neurobiology

Accès ouvert 2025 articleOpenAlex

The GECKOS survey: The formation history of a barred galaxy via structural decomposition and spatially resolved spectroscopy

A. Fraser-McKelvie, Dimitri A. Gadotti, Francesca Fragkoudi, Camila de Sá-Freitas et autres

1 citationAstronomy and Astrophysics

Accès ouvert 2025 preprintOpenAlex

Antidopaminergic Medications Are Associated with Faster Decline in Measures of Clinical Outcome in HD: Insights from PROOF-HD

Karen E. Anderson, Andrew Feigin, Ralf Reilmann, Anne Rosser et autres

1 citationmedRxiv

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.